SCHEMBL6096771

SCHEMBL6096771

CCN1C(=O)C(=O)N(c2ccc(F)cc2)C1=S

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 6/20 0.45
MEN1 O00255 5/20 0.45
POLB P06746 4/20 0.45
GAA P10253 2/20 0.45
MGLL Q99685 1/20 0.43
PARK7 Q99497 1/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
NTSR1 P30989 1/20 0.40
HTT P42858 1/20 0.40
TNFRSF1A P19438 3/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
PGR P06401 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6068021 0.83 NPC1 (0.44) NPC1SMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL6096783 0.77 PARK7 (0.46) NPC1SMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL22289536 0.73 SMN1; SMN2 (0.58) NPC1SMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL8663397 0.71 KMT2A (0.53) SMN1; SMN2KMT2AMEN1POLBGAA
SCHEMBL22289859 0.70 SMN1; SMN2 (0.82) NPC1SMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL6097897 0.70 NPC1 (0.44) NPC1SMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL19707626 0.69 MGLL (0.60) RAB9AKMT2AMEN1POLBGAA
SCHEMBL10134013 0.69 SMN1; SMN2 (0.54) NPC1SMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL22289538 0.68 SMN1; SMN2 (1.00) NPC1SMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL14712957 0.67 MAPT (0.57) NPC1SMN1; SMN2KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135492-B2 Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion WYETH (US) 2006-11-14 US disclosed
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis WYETH 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis FFAR4, FFAR1, MSR1 NPC1 25/4885SMN1; SMN2 4084/4885RAB9A 3833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.